Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1788
Name peritoneal mesothelioma
Definition A peritoneum cancer that develops from cells of the mesothelium and is located_in the peritoneum.
Source DiseaseOntology.org
Alt Ids DOID:0050874 DOID:7954
Path disease disease of cellular proliferation cancer organ system cancer peritoneum cancer peritoneal mesothelioma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00996385 Phase II Bortezomib + Oxaliplatin Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status USA 0
NCT02399371 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting USA 0
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Disodium Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Completed USA | ITA 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT03054298 Phase I HuCART-meso cells Cyclophosphamide CAR T Cells in Mesothelin Expressing Cancers Completed USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03319537 Phase Ib/II MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Terminated USA 0
NCT03399552 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma Completed USA 0
NCT03436732 Phase I LMB-100 + SVP-rapa Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Terminated USA 0
NCT03546426 Phase I Aldesleukin + Pembrolizumab Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX) Active, not recruiting ITA 0
NCT03608618 Phase I MCY-M11 Cyclophosphamide Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Terminated USA 0
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03907852 Phase Ib/II Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA | CAN 0
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04840615 Phase I Ipilimumab + LMB-100 Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma Terminated USA 0
NCT05001880 Phase II Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Recruiting USA 0
NCT05041062 Phase II Ipilimumab + Nivolumab A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Completed USA 0
NCT05071014 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Mesothelioma Completed USA 0
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Suspended USA 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Active, not recruiting USA | AUS 0
NCT05568680 Phase I SynKIR-110 SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma Recruiting USA 0
NCT06255665 Phase I JNJ-79032421 A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Recruiting ESP 0